• 059THY Banner 1150x300
  • 059THY Banner 1150x300



Thyroid cancer is one of the most prevalent cancers in the United States. An estimated 56,870 new cases are diagnosed annually, and 2,010 people die of the disease (ACS, 2017). Thyroid cancer is typically more aggressive in men than women and becomes increasingly lethal in those older than age 40 (NCCN, 2016). There are three primary subtypes: differentiated (including papillary, follicular, and Hürthle), medullary, and anaplastic. The differentiated subtype is the most common, accounting for approximately 94% of cases (ACS, 2016). Although surgical resection may be curative and 10-year survival rates are high, the dearth of data from well-designed trials has led to confusion over optimal management strategies for individual patients (NCCN, 2016). The medullary subtype accounts for 4% of cases, with nearly half presenting with unresectable or metastatic disease. No curative systemic therapies are available for these patients, and the 5-year overall survival rate is only 28% (ACS, 2016). The anaplastic subtype has the worst prognosis, with no effective therapies available. The 1-year survival rate is a dismal 20%, and the disease-specific mortality rate is nearly 100% (NCCN, 2016).


Oncologists, endocrinologists, surgeons, and other health care professionals involved in the treatment of patients with thyroid cancer.


Upon completion of this activity, participants should be able to:

  • Assess risk-adapted approaches to the management of thyroid cancer
  • Evaluate efficacy and safety data on novel therapies for differentiated and medullary thyroid cancer
  • Apply posttreatment monitoring strategies to ensure optimal outcomes for patients with thyroid cancer


Jochen Lorch, MD, MSJochen H. Lorch, MD, MS (Chairperson)
Assistant Professor of Medicine
Harvard Medical School

Tanguy Seiwert, MDTanguy Seiwert, MD
Assistant Professor of Medicine
The University of Chicago Medicine

Taofeek K. Owonikoko, MD, PhD, MSCRTaofeek K. Owonikoko, MD, PhD, MSCR
Associate Professor, Hematology & Medical Oncology
Emory University School of Medicine

Ellen Marqusee, MDEllen Marqusee, MD
Assistant Professor of Medicine
Harvard Medical School


There is no fee to participate in or claim CME credit for this activity.

Please note that Penn State College of Medicine and i3 Health do not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.

Jointly Provided by

 Penn State Hershey College of Medicine

ACCME Commendation Logo

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and i3health. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Penn State College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced. Relevant financial relationships exist between the following individuals and commercial interests:

Penn State College of Medicine staff members, i3 Health staff members, and the peer/content reviewer for this activity have no relevant financial relationships to disclose.

Jochen H. Lorch, MD, MS discloses that he has served as a consultant/advisor for Eisai and has received research grants from Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, and Millennium.

Tanguy Seiwert, MD discloses that he has served as a consultant/advisor for AstraZeneca, Eli Lilly, and Merck. He has received research grants from Bristol-Myers Squibb and Merck.

Taofeek K. Owonikoko, MD, PhD, MSCR has no relevant financial relationships to disclose.

Ellen Marqusee, MD has no relevant financial relationships to disclose.


The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.


This activity is supported by independent educational grants from Eisai and Genzyme.


If you have technical queries about this activity, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.. Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or This email address is being protected from spambots. You need JavaScript enabled to view it.. Reference course #G6195-18-Z.


The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, Penn State College of Medicine, i3 Health, or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.